Acorda Therapeutics

Acorda Therapeuticsis a biopharmaceutical company that discovers, develops, and commercializes therapies for neurological disorders. Its portfolio includes Ampyra (dalfampridine), an oral medication approved to improve walking in adults with multiple sclerosis, and Inbrija (levodopa inhalation powder), a treatment for off‑period episodes in Parkinson’s disease. The company focuses on addressing unmet medical needs in the central nervous system space, serving patients primarily in the United States while also pursuing opportunities in select international markets. Its research and development efforts are directed toward novel mechanisms and delivery systems that aim to enhance therapeutic outcomes for chronic neurologic conditions.

Acorda Therapeutics distinguishes itself through a specialization in central nervous system therapeutics and a track record of bringing FDA‑approved products to market. The company’s expertise lies in optimizing drug formulations and delivery methods, exemplified by the inhaled levodopa technology used in Inbrija. This focus positions Acorda within the specialty pharmaceutical sector, where it competes by targeting specific neurologic indications rather than pursuing broad‑spectrum pharmaceuticals. The firm’s scientific approach emphasizes rigorous clinical development and regulatory compliance to secure approvals and maintain product safety.

Acorda Therapeutics operates as an independent, publicly traded corporation listed on the NASDAQ under the ticker symbol ACOR. It is not a subsidiary of a larger parent company and does not report ownership by another entity. The firm’s headquarters are located in the United States, as indicated in the provided context. In December 2021, Acorda experienced a cyber incident whose details remain limited; the nature, scope, and impact of the attack have not been publicly disclosed, and no specific threat actors or motives have been confirmed.